Document ID: Z_2_12
Section: Molecular Biology & Genomics
Keywords: pain genetics, nociception, SCN9A, Nav1.7, congenital insensitivity to pain, TRPV1, opioid receptor, OPRM1, pain sensitivity, COMT, red hair pain, MC1R, neuropathic pain, chronic pain genetics, pain threshold, analgesic response, pharmacogenomics pain, FAAH, endocannabinoid, sodium channel
Category Tags: genetics, human-origins, neuroscience
Cross-References: Z_1_05 — Epigenetics Inheritance · L_3_06 — Pharmacogenomics Foundations · Z_4_04 — RNA Biology · R_2_06 — Neuroscience Pain · K_3_11 — Consciousness Pain
Reliability Tier: Tier 1-2 (monogenic pain disorders well-established; polygenic pain sensitivity actively researched)
Last Updated: Mar 7, 2026 | Source Count: 11 | Weighted Score: 26 | Source Confidence: [3/5] | Confidence: High

QUICK SUMMARY

Pain perception — the subjective experience triggered by actual or potential tissue damage — varies enormously across individuals, with genetic factors accounting for 25–50% of the variance in pain sensitivity (twin studies; Nielsen et al., 2012). While pain is influenced by psychological, social, and contextual factors, a substantial genetic architecture underlies individual differences in pain threshold, pain tolerance, and analgesic response. The most dramatic demonstrations come from monogenic pain disorders: SCN9A (encoding the voltage-gated sodium channel Nav1.7) — gain-of-function mutations cause erythromelalgia (burning pain attacks) and paroxysmal extreme pain disorder, while loss-of-function mutations cause congenital insensitivity to pain (CIP), a rare condition in which individuals feel no pain throughout life despite otherwise normal sensory function (Cox et al., 2006). Nav1.7 is now a major pharmaceutical target for non-opioid analgesics, though clinical trials have been disappointing due to the difficulty of selectively blocking the channel. Beyond monogenic extremes, common genetic variants modulate pain sensitivity: COMT (Val158Met polymorphism affects catecholamine metabolism and pain sensitivity), OPRM1 (A118G variant alters mu-opioid receptor function and morphine response), MC1R (red hair variant — increased pain sensitivity to certain stimuli, altered anesthetic requirements), TRPV1 (capsaicin receptor variants), and FAAH (fatty acid amide hydrolase — endocannabinoid system). GWAS of chronic pain conditions (UK Biobank, N > 380,000) have identified >100 loci, with substantial genetic overlap between chronic pain conditions and psychiatric disorders (depression, anxiety), suggesting shared biological pathways.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 SCN9A and monogenic pain disorders

• Nav1.7 (encoded by SCN9A): Voltage-gated sodium channel preferentially expressed in nociceptors (peripheral pain-sensing neurons); critical for generating action potentials in pain pathways.
• Loss-of-function mutations → CIP: Complete loss of pain perception with intact touch, pressure, temperature discrimination, and normal cognitive function; first families identified in northern Pakistan (Cox et al., 2006 — three consanguineous families with homozygous nonsense mutations); individuals suffer repeated injuries, burns, and fractures without awareness.
• Gain-of-function mutations → pain syndromes: Inherited erythromelalgia (IEM — episodic burning pain in extremities triggered by warmth; I848T and others lower activation threshold); paroxysmal extreme pain disorder (PEPD — severe rectal, ocular, submandibular pain; V1299F and others slow inactivation).
• Pharmaceutical target: Nav1.7-selective channel blockers would theoretically provide analgesia without addiction risk (unlike opioids); multiple drug candidates in clinical trials but with limited success due to insufficient selectivity, as Nav1.7 shares structural similarity with other sodium channels essential for cardiac and neural function.

1.2 Heritability of pain sensitivity

• Twin studies: Heritability estimates for experimental pain sensitivity range from 22–55% depending on modality (heat, cold, pressure, electrical); Nielsen et al. (2012) meta-analysis estimated 25–50% across multiple pain phenotypes.
• Chronic pain heritability: Migraine (h² ≈ 40–60%), low back pain (h² ≈ 30–46%), fibromyalgia (h² ≈ 50%), temporomandibular disorder (h² ≈ 35–50%) — all show substantial genetic contributions.
• UK Biobank GWAS (Johnston et al., 2019; N = 387,649): Identified 76 loci significantly associated with multisite chronic pain; implicated genes in neurogenesis, synaptic signaling, and immune function; strong genetic correlation with depression (rg ≈ 0.50), neuroticism, and BMI.

1.3 COMT Val158Met and pain

• COMT (catechol-O-methyltransferase): Metabolizes catecholamines (dopamine, epinephrine, norepinephrine); Val158Met polymorphism (rs4680): Val/Val = high COMT activity → lower pain sensitivity; Met/Met = low COMT activity → higher pain sensitivity and higher catecholamine levels.
• Functional impact: Zubieta et al. (2003) — Met/Met homozygotes showed diminished mu-opioid system activation during sustained pain and rated pain as more unpleasant; effect sizes are modest and context-dependent.
• Clinical relevance: COMT genotype influences morphine requirements post-surgery (Met carriers often require more), fibromyalgia risk, and temporomandibular pain susceptibility; replicated in multiple populations, though effect sizes are small and interactions with other genes are likely.

1.4 Opioid receptor genetics (OPRM1)

• OPRM1 A118G (rs1799971): Most studied opioid receptor variant; G allele (Asn40Asp) associated with reduced mu-opioid receptor expression, altered beta-endorphin binding, and increased morphine dose requirements for adequate analgesia (Chou et al., 2006 — post-surgical patients with AG/GG required ~30% more morphine).
• Population variation: G allele frequency varies substantially by ancestry — ~15% in European populations, ~40–50% in East Asian populations, ~1–3% in African populations; contributes to inter-ethnic variation in opioid response.
• Addiction risk: A118G has been studied in relation to alcohol and opioid use disorder risk with inconsistent results; recent large GWAS suggest OPRM1 variants contribute modestly to addiction susceptibility.

2. CREDIBLE BUT DEBATED CLAIMS (Tier 2 — Academic / Debated)

2.1 Red hair, MC1R, and pain

• MC1R (melanocortin-1 receptor): Loss-of-function variants (R151C, R160W, D294H) produce the red hair/fair skin phenotype; also influence pain and anesthetic response — red-haired individuals require ~20% more inhaled anesthetic (desflurane) for surgical immobility (Liem et al., 2004) and report greater fear of dental pain.
• Mechanism: MC1R is expressed in pain pathways; melanocortins modulate opioid signaling; the relationship between MC1R variants and pain processing is bidirectional — increased sensitivity to some pain modalities, altered response to kappa-opioid agonists.
• Debate: Not all studies replicate the anesthetic finding; effect sizes are clinically meaningful if real but the mechanism is not fully understood.

2.2 FAAH and endocannabinoid analgesia

• FAAH (fatty acid amide hydrolase): Degrades endocannabinoids (anandamide); rare loss-of-function variant (FAAH-OUT microdeletion) identified in a Scottish woman (Jo Cameron) with lifelong pain insensitivity, rapid wound healing, and reduced anxiety (Habib et al., 2019); she had undergone hand surgery and hip replacement with minimal postoperative pain.
• Common variants: FAAH 385C>A (rs324420, Pro129Thr) — threonine allele associated with lower FAAH expression, higher anandamide levels, and modestly reduced pain sensitivity; FAAH inhibitors are in development as non-opioid analgesics.

2.3 Sex differences in pain genetics

• Females consistently report greater pain sensitivity, more chronic pain conditions, and higher prevalence of fibromyalgia, migraine, and TMD; sex hormones modulate pain pathways — estrogen can be pro- or anti-nociceptive depending on dose and pain type; genetic risk variants may have sex-specific effects; X-chromosome genes (including some ion channels) may contribute; large-sample GWAS are beginning to model sex-stratified genetic architectures.

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Personalized pain therapy based on genotype

Clinical implementation of pain pharmacogenomics (matching analgesic type and dose to genotype — CYP2D6 for codeine, OPRM1 for morphine, COMT for catecholamine-based mechanisms) is conceptually promising but not yet standard care; effect sizes of individual variants are small; multigene algorithms are in development but lack sufficient clinical validation.

3.2 Epigenetic mechanisms in chronic pain

Chronic pain conditions show altered DNA methylation and histone modifications in dorsal root ganglia and central pain-processing regions; whether these epigenetic changes are causes, consequences, or both is unclear; methylation status at pain-relevant genes (e.g., TRPA1, OPRM1 promoter) may mediate the transition from acute to chronic pain.

4. DUBIOUS OR FRINGE CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 "Pain is purely psychological"

While psychological factors modulate pain (catastrophizing, expectation, attention), pain has a robust biological substrate with identifiable molecular, neural, and genetic components; dismissing pain as "in your head" is contradicted by massive neuroscience evidence and is harmful to patients.

4.2 Genetic determinism of pain experience

Genetics accounts for 25–50% of variance — substantial but not deterministic; psychological, social, cultural, and contextual factors contribute equally or more; the biopsychosocial model of pain (Gatchel et al., 2007) is the current standard.

IMAGES

Counter-Arguments & Criticisms

No significant counter-arguments exist in the scholarly literature for the core claims presented here. The topic of Genetics Pain Perception represents established knowledge within molecular biology and biochemistry with no active scholarly dispute over the fundamental claims presented in this document.

BIBLIOGRAPHY

1. Cox, James J., et al | 2006 | "An SCN9A Channelopathy Causes Congenital Inability to Experience Pain" | Nature | ∅ | 444::894–898 | ∅ | ∅ | doi:10.1038/nature05413 | ∅ | ∅ | ∅
2. Nielsen, Christopher S., et al | 2008 | "Individual Differences in Pain Sensitivity: Genetic and Environmental Contributions" | Pain | ∅ | 136::21–29 | ∅ | ∅ | doi:10.1016/j.pain.2007.06.008 | ∅ | ∅ | ∅
3. Johnston, Keira J | 2019 | "Genome-Wide Association Study of Multisite Chronic Pain in UK Biobank" | PLOS Genetics | ∅ | 15:: | A., et al. e1008164 | ∅ | doi:10.1371/journal.pgen.1008164 | ∅ | ∅ | ∅
4. Zubieta, Jon-Kar, et al | 2003 | "COMT Val158Met Genotype Affects Mu-Opioid Neurotransmitter Responses to a Pain Stressor" | Science | ∅ | 299::1240–1243 | ∅ | ∅ | doi:10.1126/science.1078546 | ∅ | ∅ | ∅
5. Chou, Wan-Yu, et al | 2006 | "Human Opioid Receptor A118G Polymorphism Affects Intravenous Patient-Controlled Analgesia Morphine Consumption after Total Abdominal Hysterectomy" | Anesthesiology | ∅ | 105::334–337 | ∅ | ∅ | doi:10.1097/00000542-200608000-00016 | ∅ | ∅ | ∅
6. Liem, Edwin B., et al | 2004 | "Anesthetic Requirement Is Increased in Redheads" | Anesthesiology | ∅ | 101::279–283 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
7. Habib, Abdella M., et al. e249 e253 | 2019 | "Microdeletion in a FAAH Pseudogene Identified in a Patient with High Anandamide Concentrations and Pain Insensitivity" | British Journal of Anaesthesia | ∅ | 123:: | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
8. Basbaum, Allan I., et al | 2009 | "Cellular and Molecular Mechanisms of Pain" | Cell | ∅ | 139::267–284 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
9. Mogil, Jeffrey S | 2012 | "Pain Genetics: Past, Present and Future" | Trends in Genetics | ∅ | 28::258–266 | ∅ | ∅ | doi:10.1016/j.tig.2012.01.002 | ∅ | ∅ | ∅
10. Dib-Hajj, Sulayman D., et al | 2010 | "Sodium Channels in Human Pain Disorders: Genetics and Pharmacogenomics" | Annual Review of Neuroscience | ∅ | 33::325–347 | ∅ | ∅ | doi:10.1146/annurev-neuro-060909-153234 | ∅ | ∅ | ∅
11. Fillingim, Roger B., et al | 2009 | "Sex, Gender, and Pain: A Review of Recent Clinical and Experimental Findings" | Journal of Pain | ∅ | 10.5::447–485 | ∅ | ∅ | doi:10.1016/j.jpain.2008.12.001 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

• Z_1_05 — Epigenetics Inheritance: Epigenetic mechanisms in chronic pain
• L_3_06 — Pharmacogenomics: CYP2D6 codeine metabolism, opioid pharmacogenomics
• Z_4_04 — RNA Biology: miRNA regulation in pain pathways
• R_2_06 — Neuroscience Pain: Neural circuits of nociception
• K_3_11 — Consciousness Pain: Subjective experience of pain

Last verified: Mar 07, 2026 — All sources peer-reviewed or from established genetics/neuroscience literature